Correlation between pain response and improvements in patient-reported outcomes and health-related quality of life in duloxetine-treated patients with diabetic peripheral neuropathic pain

Neuropsychiatric Disease and Treatment

Volumn 11, Issue , 2015, Pages 2101-2107

  Ogawa, Kei ^a   Fujikoshi, Shinji ^a   Montgomery, William ^b   Alev, Levent ^a  

^a ELI LILLY AND COMPANY   (United States)

^b ELI LILLY AUSTRALIA PTY LTD   (Australia)

Author keywords

Diabetic peripheral neuropathic pain; Duloxetine; Efficacy; Function; Quality of life

Indexed keywords

DULOXETINE; PLACEBO;

ADULT; AGED; ANALGESIA; ARTICLE; CONTROLLED STUDY; CORRELATIONAL STUDY; DIABETIC PERIPHERAL NEUROPATHIC PAIN; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; EUROQOL QUESTIONNAIRE FIVE DIMENSION VERSION; FEMALE; FUNCTIONAL STATUS ASSESSMENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUROPATHIC PAIN; OUTCOME ASSESSMENT; PAIN SEVERITY; PATIENT GLOBAL IMPRESSION OF IMPROVEMENT; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SHORT FORM 36; TREATMENT DURATION;

EID: 84939803553     PISSN: None     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/NDT.S87665     Document Type: Article

References (18)

1. Davies M, Brophy S, Williams R, Taylor A. The prevalence, severity, and impact of painful diabetic peripheral neuropathy in type 2 diabetes. Diabetes Care. 2006;29(7):1518–1522.
2. Daousi C, MacFarlane IA, Woodward A, Nurmikko TJ, Bundred PE, Benbow SJ. Chronic painful peripheral neuropathy in an urban community: a controlled comparison of people with and without diabetes. Diabet Med. 2004;21(9):976–982.
3. Berger A, Dukes EM, Oster G. Clinical characteristics and economic costs of patients with painful neuropathic disorders. J Pain. 2004;5(3):143–149.
4. Perahia DG, Pritchett YL, Desaiah D, Raskin J. Efficacy of duloxetine in painful symptoms: an analgesic or antidepressant effect? Int Clin Psychopharmacol. 2006;21(6):311–317.
5. Goldstein DJ, Lu Y, Detke MJ, Lee TC, Iyengar S. Duloxetine vs placebo in patients with painful diabetic neuropathy. Pain. 2005;116(1–2):109–118.
6. Wernicke JF, Pritchett YL, D’Souza DN, et al. A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain. Neurology. 2006;67(8):1411–1420.
7. Raskin J, Pritchett YL, Wang F, et al. A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. Pain Med. 2005;6(5):346–356.
8. Armstrong DG, Chappell AS, Le TK, et al. Duloxetine for the management of diabetic peripheral neuropathic pain: evaluation of functional outcomes. Pain Med. 2007;8(5):410–418.
9. Ware JE, Snow KK, Kosinski M, Gandek B. SF-36 Health Survey Manual and Interpretation Guide. Boston, MA: New England Medical Center, the Health Institute; 1993.
10. EuroQol Research Foundation [homepage on the Internet]. EQ-5D. Rotterdam, the Netherlands: EuroQol Research Foundation; 2015. Available from: http://www.euroqol.org/. Accessed June 10, 2015.
11. Guy W. ECDEU Assessment Manual for Psychopharmacology – Revised. Rockville, MD: US Department of Health, Education and Welfare, ADAMHA, MIMH Psychopharmacology Research Branch; 1976.
12. Farrar JT, Pritchett YL, Robinson M, Prakash A, Chappell A. The clinical importance of changes in the 0 to 10 numeric rating scale for worst, least, and average pain intensity: analyses of data from clinical trials of duloxetine in pain disorders. J Pain. 2010;11(2):109–118.
13. Hoffman DL, Dukes EM. The health status burden of people with fibromyalgia: a review of studies that assessed health status with the SF-36 or the SF-12. Int J Clin Pract. 2008;62(1):115–126.
14. Vinik A, Emir B, Cheung R, Whalen E. Relationship between pain relief and improvements in patient function/quality of life in patients with painful diabetic peripheral neuropathy or postherpetic neuralgia treated with pregabalin. Clin Ther. 2013;35(5):612–623.
15. Walters SJ, Brazier JE. Comparison of the minimally important difference for two health state utility measures: EQ-5D and SF-6D. Qual Life Res. 2005;14(6):1523–1532.
16. Saarni SI, Härkänen T, Sintonen H, et al. The impact of 29 chronic conditions on health-related quality of life: a general population survey in Finland using 15D and EQ-5D. Qual Life Res. 2006;15(8):1403–1414.
17. Gore M, Brandenburg NA, Dukes E, Hoffman DL, Tai KS, Stacey B. Pain severity in diabetic peripheral neuropathy is associated with patient functioning, symptom levels of anxiety and depression, and sleep. J Pain Symptom Manage. 2005;30(4):374–385.
18. Stewart AL, Greenfield S, Hays RD, et al. Functional status and well-being of patients with chronic conditions. Results from the Medical Outcomes Study. JAMA. 1989;262(7):907–913.